SOLAR: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
Study Details
Study Description
Brief Summary
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Participants receiving CAB LA + RPV LA regimen Participants will be offered the option to start with a month long oral lead in or to start long acting intramuscular (IM) injections (oral lead in [OLI] or direct to injection [D2I]). On Day 1, participants who choose to participate in OLI will be administered CAB + RPV orally for one month. At the Month 1 visit, last dose of oral CAB + RPV will be given followed by the first CAB LA + RPV LA IM injection. The second IM injection with CAB LA and RPV LA will be administered at Month 2 followed by the same administered every 2 months (Q2M) until Month 12. In D2I, at Day 1, eligible participants will receive the first injection of CAB LA + RPV LA as initial loading dose. The second and third injections (CAB LA + RPV LA) will be administered at Month 1 and Month 3 followed by the same Q2M until Month 11. |
Drug: Cabotegravir Tablets
CAB tablets will be available as film coated tablets for oral administration.
Drug: Cabotegravir Injectable Suspension (CAB LA)
CAB LA will be available as sterile suspension for injection in GSK1265744 for administration as IM injection.
Drug: Rilpivirine Tablets
RPV will be administered as tablets for oral administration.
Drug: Rilpivirine Injectable Suspension (RPV LA)
RPV LA will be available as a sterile suspension of RPV to be administered as an IM injection.
|
| Active Comparator: Participants receiving BIK Participants will receive BIK, that is a combination of Bictegravir (BIC) + Emtricitabine (FTC) + Tenofovir alafenamide (TAF) orally, administered until Month 12. |
Drug: BIKTARVY Tablets (BIK)
BIK will be a three-drug fixed dose combination product BIC, FTC, and TAF for oral administration.
|
Outcome Measures
Primary Outcome Measures
- Percentage of participants with plasma HIV-1 ribonucleic acid (RNA) greater than or equal to (>=) 50 copies per milliliter (c/mL) - OLI [At Month 12]
- Percentage of participants with plasma HIV-1 RNA >=50 c/mL - D2I [At Month 11]
- Percentage of participants with plasma HIV-1 RNA >=50 c/mL - BIK [At Month 12]
Secondary Outcome Measures
- Percentage of participants with plasma HIV-1 RNA less than (<)50 c/mL - OLI [At Months 6 and 12]
- Percentage of participants with plasma HIV-1 RNA <50 c/mL - D2I [At Months 5 and 11]
- Percentage of participants with plasma HIV-1 RNA <50 c/mL - BIK [At Months 6 and 12]
- Percentage of participants with protocol-defined confirmed virologic failure (CVF) - OLI [Up to Month 12]
- Percentage of participants with protocol-defined CVF - D2I [Up to Month 11]
- Percentage of participants with protocol-defined CVF - BIK [Up to Month 12]
- Percentage of participants with HIV-RNA >=50 c/mL - OLI [At Month 6]
- Percentage of participants with HIV-RNA >=50 c/mL - D2I [At Month 5]
- Percentage of participants with HIV-RNA >=50 c/mL - BIK [At Month 6]
- Absolute values of HIV viral load - OLI [Up to Month 12]
- Absolute values of HIV viral load - D2I [Up to Month 11]
- Absolute values of HIV viral load - BIK [Up to Month 12]
- Change from Baseline in HIV viral load (c/mL) - OLI [Baseline (Day 1) and up to Month 12]
- Change from Baseline in HIV viral load (c/mL) - D2I [Baseline (Day 1) and up to Month 11]
- Change from Baseline in HIV viral load (c/mL) - BIK [Baseline (Day 1) and up to Month 12]
- Absolute values of cluster of differentiation 4 plus (CD4+) cell counts - OLI [Up to Month 12]
- Absolute values of CD4+ cell counts - D2I [Up to Month 11]
- Absolute values of CD4+ cell counts - BIK [Up to Month 12]
- Change from Baseline in CD4+ cell counts (Cells per cubic millimeters [cells/mm^3]) - OLI [Baseline (Day 1) and up to Month 12]
- Change from Baseline in CD4+ cell counts (cells/mm^3) - D2I [Baseline (Day 1) and up to Month 11]
- Change from Baseline in CD4+ cell counts (cells/mm^3) - BIK [Baseline (Day 1) and up to Month 12]
- Number of participants with treatment-emergent phenotypic resistance - OLI [Up to Month 12]
- Number of participants with treatment-emergent phenotypic resistance - D2I [Up to Month 11]
- Number of participants with treatment-emergent phenotypic resistance - BIK [Up to Month 12]
- Number of participants with treatment-emergent genotypic resistance - OLI [Up to Month 12]
- Number of participants with treatment-emergent genotypic resistance - D2I [Up to Month 11]
- Number of participants with treatment-emergent genotypic resistance - BIK [Up to Month 12]
- Change from Baseline in Cystatin C in blood - OLI [Baseline (Day 1) and at Months 6 and 12]
- Change from Baseline in Cystatin C in blood - D2I [Baseline (Day 1) and at Months 5 and 11]
- Change from Baseline in Cystatin C in blood - BIK [Baseline (Day 1) and at Months 6 and 12]
- Change from Baseline in retinol binding protein in blood - OLI [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in retinol binding protein in blood - D2I [Baseline (Day 1) and At Months 5 and 11]
- Change from Baseline in retinol binding protein in blood - BIK [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in retinol binding protein in urine - OLI [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in retinol binding protein in urine - D2I [Baseline (Day 1) and At Months 5 and 11]
- Change from Baseline in retinol binding protein in urine - BIK [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in Beta-2-microglobulin in blood - OLI [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in Beta-2-microglobulin in blood - D2I [Baseline (Day 1) and At Months 5 and 11]
- Change from Baseline in Beta-2-microglobulin in blood - BIK [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in Beta-2-microglobulin in urine - OLI [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in Beta-2-microglobulin in urine - D2I [Baseline (Day 1) and At Months 5 and 11]
- Change from Baseline in Beta-2-microglobulin in urine - BIK [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in bone-specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin (micrograms per liter) - OLI [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in bone-specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin (micrograms per liter) - D2I [Baseline (Day 1) and At Months 5 and 11]
- Change from Baseline in bone-specific alkaline phosphatase, procollagen type 1 N-propeptide, type 1 collagen cross-linked C-telopeptide, osteocalcin (micrograms per liter) - BIK [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in 25 hydroxy-Vitamin D - OLI [Baseline (Day 1) and At Months 6 and 12]
- Change from Baseline in 25 hydroxy-Vitamin D - D2I [Baseline (Day 1) and At Months 5 and 11]
- Change from Baseline in 25 hydroxy-Vitamin D - BIK [Baseline (Day 1) and At Months 6 and 12]
- Percentage of participants with Metabolic syndrome - OLI [At Months 6 and 12]
Metabolic syndrome is a cluster of conditions that occurs together increasing one's risk of heart disease, stroke and type 2 diabetes mellitus (DM). These conditions include increased blood pressure (BP), elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and triglyceride (TG) levels.
- Percentage of participants with Metabolic syndrome - D2I [At Months 5 and 11]
Metabolic syndrome is a cluster of conditions that occurs together increasing one's risk of heart disease, stroke and type 2 DM. These conditions include increased BP, elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and TG levels.
- Percentage of participants with Metabolic syndrome - BIK [At Months 6 and 12]
Metabolic syndrome is a cluster of conditions that occurs together increasing one's risk of heart disease, stroke and type 2 DM. These conditions include increased BP, elevated blood glucose levels, excess body fat around the waist and abnormal fasting cholesterol and TG levels.
- Change From Baseline in Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR) - OLI [Baseline (Day 1) and At Months 6 and 12]
Insulin resistance will be assessed using HOMA-IR index.
- Change From Baseline in HOMA-IR - D2I [Baseline (Day 1) and At Months 5 and 11]
Insulin resistance will be assessed using HOMA-IR index.
- Change From Baseline in HOMA-IR - BIK [Baseline (Day 1) and At Months 6 and 12]
Insulin resistance will be assessed using HOMA-IR index.
- Percentage of participants with their treatment Preference as Assessed Using Preference Questionnaire - OLI [At Month 12]
The "Preference" questionnaire will include 3 questions and assess whether participants prefer the CAB LA + RPV LA injectable treatment or the daily oral antiretroviral (ARV) regimen, also evaluating the attributes supporting this preference.
- Percentage of participants with their Treatment Preference as Assessed Using Preference Questionnaire - D2I [At Month 11]
The "Preference" questionnaire will include 3 questions and assess whether participants prefer the CAB LA + RPV LA injectable treatment or the daily oral ARV regimen, also evaluating the attributes supporting this preference.
- Change From Baseline in Total Treatment Satisfaction Score using HIV Treatment Satisfaction Status Questionnaire (HIVTSQs) (scores on a scale) - OLI [Baseline (Day 1) and at Months 6 and 12]
The HIVTSQs treatment satisfaction questionnaire comprises of 1-12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a score with a possible range of 0 to 66. Higher scores represent greater treatment satisfaction as compared to the past few weeks.
- Change From Baseline in Total Treatment Satisfaction Score using HIVTSQs (scores on a scale) - D2I [Baseline (Day 1) and at Months 5 and 11]
The HIVTSQs treatment satisfaction questionnaire comprises of 1-12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a score with a possible range of 0 to 66. Higher scores represent greater treatment satisfaction as compared to the past few weeks.
- Change From Baseline in Total Treatment Satisfaction Score using HIVTSQs (scores on a scale)- BIK [Baseline (Day 1) and at Months 6 and 12]
The HIVTSQs treatment satisfaction questionnaire comprises of 1-12 questions and the total treatment satisfaction score is computed with items 1-11 and summed to produce a score with a possible range of 0 to 66. Higher scores represent greater treatment satisfaction as compared to the past few weeks.
- Change From Baseline in individual item scores using HIVTSQs (scores on a scale) - OLI [Baseline (Day 1) and at Months 6 and 12]
HIVTSQs is a 12 item questionnaire. The individual item scores on HIVTSQs scale are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment.
- Change From Baseline in individual item scores using HIVTSQs (scores on a scale) - D2I [Baseline (Day 1) and at Months 5 and 11]
HIVTSQs is a 12 item questionnaire. The individual item scores on HIVTSQs scale are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment.
- Change From Baseline in individual item scores using HIVTSQs (scores on a scale) - BIK [Baseline (Day 1) and at Months 6 and 12]
HIVTSQs is a 12 item questionnaire. The individual item scores on HIVTSQs scale are rated as 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). Higher scores represent greater satisfaction with each aspect of treatment.
- Change from Baseline in Total treatment satisfaction score using the HIV Treatment Satisfaction Change Questionnaire (HIVTSQc)- OLI [Baseline (Day 1) and At Month 12]
The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.
- Change from Baseline in Total treatment satisfaction score using HIVTSQc - D2I [Baseline (Day 1) and At Month 11]
The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.
- Change from Baseline in Total treatment satisfaction score using HIVTSQc - BIK [Baseline (Day 1) and At Month 12]
The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.
- Change From Baseline in individual item scores using HIVTSQc - OLI [Baseline (Day 1) and Month 12]
The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.
- Change From Baseline in individual item scores using HIVTSQcs - D2I [Baseline (Day 1) and Months 11]
The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.
- Change From Baseline in individual item scores using HIVTSQc - BIK [Baseline (Day 1) and Months 12]
The HIVTSQc is a 1-12 items questionnaire. Each item is scored -3 to 3. Total treatment satisfaction change score is computed using items 1 to 11 and are summed to produce a score with a possible range of -33 to 33. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 will represent no change.
- Change from Month 2 in Dimension Scores Using Perception of Injection (PIN) Questionnaire - OLI [Month 2 and At Months 6, and 12]
The PIN questionnaire explores the bother of pain at the injection site and injection site reaction (ISRs), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections. This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is always equated with the most favorable perception of vaccination, and 5 is the most unfavorable.
- Change from Month 1 in Dimension Scores Using PIN Questionnaire - D2I [Month 1 and At Months 5, and 11]
The PIN questionnaire explores the bother of pain at the injection site and ISRs, anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections. This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. The items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is always equated with the most favorable perception of vaccination, and 5 is the most unfavorable.
- Change From Month 2 in individual item scores Using PIN Questionnaire - OLI [Month 2 and at Months 6 and 12]
The PIN questionnaire explores the bother of pain at the injection site and ISRs, anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections. This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Each individual items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is always equated with the most favorable perception of vaccination, and 5 is the most unfavorable.
- Change From Month 1 in individual item scores Using PIN Questionnaire - D2I [Month 1 and at Months 5 and 11]
The PIN questionnaire explores the bother of pain at the injection site and ISRs, anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections. This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial. Each individual items in the scale are rated on a 5-point scale and questions are phrased in such a way as to ensure that 1 is always equated with the most favorable perception of vaccination, and 5 is the most unfavorable.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants aged 18 years or older (or >=19 where required by local regulatory agencies), at the time of signing the informed consent.
-
A female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies.
- Non-reproductive potential defined as:
- Pre-menopausal females with one of the following:
-
Documented tubal ligation.
-
Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion.
-
Hysterectomy.
-
Documented Bilateral Oophorectomy
- Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.
- Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, throughout the study, for at least 30 days after discontinuation of all oral study medications, and for at least 52 weeks after discontinuation of CAB LA and RPV LA.
-
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. Eligible participants or their legal guardians (and next of kin when locally required), must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrollment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures.
-
Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category.
-
Must be on the uninterrupted current regimen of BIK for at least 6 months prior to Screening with an undetectable HIV-1 viral load for at least 6 months prior to Screening. BIK must be the participant's first or second regimen. If BIK is the second regimen, the first regimen must be an integrase inhibitor (INI) regimen. Only a single prior Integrase inhibitor (INI) regimen is allowed if BIK is a second line regimen >=6 months prior to screening. Any history of non-integrase strand transfer inhibitor regimens (that is. non-nucleoside reverse transcriptase inhibitor, protease inhibitor, C-C chemokine receptor 5 and other entry inhibitors) are not permitted. Any prior change in regimen, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must not have been done for treatment failure (HIV-1 RNA >=400 c/mL).
The following are limited exceptions:
-
A change from Tenofovir disoproxil fumarate (TDF) to TAF will not be considered a regimen change.
-
Historical perinatal use of Nucleoside reverse transcriptase inhibitor (NRTI) when given in addition to an ongoing Highly active antiretroviral therapy (HAART) will not be considered a change in ART therapy regimen.
-
The past use of ARVs in the context of Post Exposure Prophylaxis (PEP) or Pre-Exposure Prophylaxis (PrEP) while the participant was HIV negative will be allowed. Such cases will be evaluated on a case by case basis with the Medical Monitor, and may require documentation of HIV negative serology during time of PEP or PrEP.
-
A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy.
-
A change in formulation from multiple class regimens to single treatment regimens (of the same medications) would not be considered a change in ART regimen.
-
Documented evidence of plasma HIV-1 RNA measurements <50 c/mL in the 6 months prior to Screening.
-
Plasma HIV-1 RNA <50 c/mL at Screening.
Exclusion Criteria:
-
Within 6 months prior to Screening, any plasma HIV-1 RNA measurement >=50 c/mL.
-
Within the 6 to 12-month window prior to Screening, documented evidence of any plasma HIV-1 RNA measurement greater than (>)200 c/mL, or 2 or more plasma HIV-1 RNA measurements >=50 c/mL.
-
History of prior treatment failure to any Department of Health and Human Services (DHHS) recommended ART regimen.
-
History of drug holiday >1 month for any reason prior to Screening visit, except where all ART was stopped due to tolerability and/or safety concerns.
-
Any change to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV 1 RNA measurement >=200 c/mL after initial suppression to <50 c/mL while on first line HIV therapy regimen).
-
Participants who are currently participating in or anticipate being selected for any other interventional study.
-
Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study.
-
Any evidence of a current Center for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy, and CD4+ counts <200 cells/microliter are not exclusionary.
-
Participants with moderate to severe hepatic impairment.
-
Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
-
Participants determined by the Investigator to have a high risk of seizures, including participants with an unstable or poorly controlled seizure disorder. A participant with a prior history of seizure may be considered for enrollment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrollment.
-
All participants will be screened for syphilis.
-
Participants with untreated secondary (late latent) or tertiary syphilis infection, defined as a positive rapid plasma reagin (RPR) and a positive treponemal test without clear documentation of treatment, are excluded.
-
Participants with a false positive RPR (with negative treponemal test) or serofast RPR result (persistence of a reactive nontreponemal syphilis test despite history of adequate therapy and no evidence of re-exposure) may enroll after consultation with the Medical Monitor.
-
Participants with primary syphilis or early latent secondary syphilis (acquired within the preceding year) who have a positive RPR test and have not been treated may be treated during the screening period and if completion of antibiotic treatment occurs during the screening period, may be allowed entry after consultation with the Medical Monitor. If antibiotic treatment cannot be completed before the screening window ends, participants may be rescreened once following completion of antibiotic therapy for primary or early latent secondary syphilis.
-
Participants who, in the investigator's judgment, pose a significant suicide risk. Participant's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
-
The participant has a tattoo, gluteal implant/enhancements or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions.
-
Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV deoxyribonucleic acid (DNA) as follows:
-
Participants positive for HBsAg are excluded.
-
Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status), whether negative or positive for HBV DNA, are excluded.
- Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; participants who require or qualify for immediate HCV treatment are excluded for those co-infected participants who post entry into Switch Onto Long Acting Regimen (SOLAR) decide treatment for HCV infection is warranted or desired either by the participant or by the treating physician.
Participants with HCV co-infection will be allowed entry into this study if:
-
Liver enzymes meet entry criteria
-
HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the Month 14 visit. Additional information (where available) on participants with HCV co-infection at screening should include results from any liver biopsy, Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment.
-
In the event that recent biopsy or imaging data is not available or inconclusive, the fibrosis (Fib)-4 score will be used to verify eligibility
- Fib-4 score >3.25 is exclusionary ii. Fib-4 scores 1.45-3.25 requires Medical Monitor consultation Fibrosis 4 Score Formula: d. Age x aspartate aminotransferase (AST)/ Platelets x (square [Alanine aminotransferase ]).
-
Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis, or decompensated cirrhosis [for example ascites, encephalopathy, or variceal bleeding]), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).
-
History of liver cirrhosis with or without hepatitis viral co-infection.
-
Ongoing or clinically relevant pancreatitis
-
Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease.
-
Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the participant prior to randomization.
-
Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive study medication.
-
History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during pharmacokinetic (PK) sampling, participants with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled.
-
Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (less than or equal to [<=]325 milligram) or hereditary coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.
-
Corrected QT interval (QTc [Bazett]) >450 milliseconds (msec) or QTc (Bazett) >480 msec for participants with bundle branch block.
-
Known or suspected active Coronavirus Disease-2019 (COVID-19) infection or has had contact with an individual with known COVID-19, within 14 days of study enrollment.
-
Known or suspected presence of resistance mutations as defined by the International Antiviral Society-United States of America (IAS-USA) resistance guidelines to the individual components of BIK (BIC, FTC, TAF), RPV, and CAB by any historical resistance test result.
-
Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening phase to verify a result.
-
Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
-
Participant has estimated creatine clearance <30mL/minute per 1.73 meter square (m^2) via Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) Method.
-
ALT >=3 times upper limit of normal (ULN).
-
Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study.
-
Treatment with any of the following agents within 28 days of Screening:
-
radiation therapy;
-
cytotoxic chemotherapeutic agents;
-
tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid/INH);
-
anti-coagulation agents;
-
Immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons.
-
Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
-
Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of study Day 1. Treatment with acyclovir/valacyclovir is permitted.
-
Use of medications which are associated with Torsade de Pointes.
-
Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | GSK Investigational Site | Bakersfield | California | United States | 93301 |
| 2 | GSK Investigational Site | Beverly Hills | California | United States | 90211 |
| 3 | GSK Investigational Site | Los Angeles | California | United States | 90027 |
| 4 | GSK Investigational Site | Los Angeles | California | United States | 90033 |
| 5 | GSK Investigational Site | Los Angeles | California | United States | 90036 |
| 6 | GSK Investigational Site | Palm Springs | California | United States | 92262 |
| 7 | GSK Investigational Site | San Francisco | California | United States | 94102 |
| 8 | GSK Investigational Site | Denver | Colorado | United States | 80204 |
| 9 | GSK Investigational Site | New Haven | Connecticut | United States | 06510 |
| 10 | GSK Investigational Site | Fort Pierce | Florida | United States | 34982 |
| 11 | GSK Investigational Site | Miami | Florida | United States | 33133 |
| 12 | GSK Investigational Site | Pensacola | Florida | United States | 32503 |
| 13 | GSK Investigational Site | Tampa | Florida | United States | 33602 |
| 14 | GSK Investigational Site | West Palm Beach | Florida | United States | 33407 |
| 15 | GSK Investigational Site | Atlanta | Georgia | United States | 30033 |
| 16 | GSK Investigational Site | Chicago | Illinois | United States | 60612 |
| 17 | GSK Investigational Site | Chicago | Illinois | United States | 60613 |
| 18 | GSK Investigational Site | Kansas City | Kansas | United States | 66160 |
| 19 | GSK Investigational Site | Wichita | Kansas | United States | 67214 |
| 20 | GSK Investigational Site | New Orleans | Louisiana | United States | 70112 |
| 21 | GSK Investigational Site | New Orleans | Louisiana | United States | 70117 |
| 22 | GSK Investigational Site | Baltimore | Maryland | United States | 21201 |
| 23 | GSK Investigational Site | Boston | Massachusetts | United States | 02043 |
| 24 | GSK Investigational Site | Boston | Massachusetts | United States | 02115 |
| 25 | GSK Investigational Site | Southfield | Michigan | United States | 48075 |
| 26 | GSK Investigational Site | Newark | New Jersey | United States | 07103 |
| 27 | GSK Investigational Site | Bronx | New York | United States | 10467 |
| 28 | GSK Investigational Site | Syracuse | New York | United States | 13210 |
| 29 | GSK Investigational Site | Durham | North Carolina | United States | 27710 |
| 30 | GSK Investigational Site | Greensboro | North Carolina | United States | 27401-1209 |
| 31 | GSK Investigational Site | Greenville | North Carolina | United States | 27834 |
| 32 | GSK Investigational Site | Huntersville | North Carolina | United States | 28078 |
| 33 | GSK Investigational Site | Wilmington | North Carolina | United States | 28401 |
| 34 | GSK Investigational Site | Toledo | Ohio | United States | 43614 |
| 35 | GSK Investigational Site | Philadelphia | Pennsylvania | United States | 19107 |
| 36 | GSK Investigational Site | Bellaire | Texas | United States | 77401 |
| 37 | GSK Investigational Site | Dallas | Texas | United States | 75208 |
| 38 | GSK Investigational Site | Dallas | Texas | United States | 75246 |
| 39 | GSK Investigational Site | Houston | Texas | United States | 77098 |
| 40 | GSK Investigational Site | Seattle | Washington | United States | 98104 |
| 41 | GSK Investigational Site | Milwaukee | Wisconsin | United States | 53226 |
| 42 | GSK Investigational Site | Darlinghurst, Sydney | New South Wales | Australia | 2010 |
| 43 | GSK Investigational Site | Darlinghurst | New South Wales | Australia | 2010 |
| 44 | GSK Investigational Site | Sydney | New South Wales | Australia | 2010 |
| 45 | GSK Investigational Site | Prahran | Victoria | Australia | 3181 |
| 46 | GSK Investigational Site | Innsbruck | Austria | A-6020 | |
| 47 | GSK Investigational Site | Linz | Austria | 4021 | |
| 48 | GSK Investigational Site | Wien | Austria | A-1090 | |
| 49 | GSK Investigational Site | Hasselt | Belgium | 3500 | |
| 50 | GSK Investigational Site | Leuven | Belgium | 3000 | |
| 51 | GSK Investigational Site | Liege | Belgium | 4000 | |
| 52 | GSK Investigational Site | Lodelinsart | Belgium | 6042 | |
| 53 | GSK Investigational Site | Winnipeg | Manitoba | Canada | R3A 1R9 |
| 54 | GSK Investigational Site | Ottawa | Ontario | Canada | K1H 8L6 |
| 55 | GSK Investigational Site | Toronto | Ontario | Canada | M5B 1W8 |
| 56 | GSK Investigational Site | Toronto | Ontario | Canada | M5G 1K2 |
| 57 | GSK Investigational Site | Toronto | Ontario | Canada | M5G 2N2 |
| 58 | GSK Investigational Site | Montreal | Quebec | Canada | H2L 4E9 |
| 59 | GSK Investigational Site | Montreal | Quebec | Canada | H2L 4P9 |
| 60 | GSK Investigational Site | Montreal | Quebec | Canada | H4A 3J1 |
| 61 | GSK Investigational Site | Montréal | Quebec | Canada | H3A 1T1 |
| 62 | GSK Investigational Site | Regina | Saskatchewan | Canada | S4P 0W5 |
| 63 | GSK Investigational Site | Bobigny | France | 93009 | |
| 64 | GSK Investigational Site | Bordeaux Cedex | France | 33076 | |
| 65 | GSK Investigational Site | Clermont-Ferrand | France | 63000 | |
| 66 | GSK Investigational Site | Créteil | France | 94010 | |
| 67 | GSK Investigational Site | Le Kremlin-Bicetre Cedex | France | 94275 | |
| 68 | GSK Investigational Site | Nantes | France | 44093 | |
| 69 | GSK Investigational Site | Nice cedex 3 | France | 06202 | |
| 70 | GSK Investigational Site | Tourcoing cedex | France | 59208 | |
| 71 | GSK Investigational Site | Muenchen | Bayern | Germany | 80336 |
| 72 | GSK Investigational Site | Aachen | Nordrhein-Westfalen | Germany | 52062 |
| 73 | GSK Investigational Site | Bochum | Nordrhein-Westfalen | Germany | 44787 |
| 74 | GSK Investigational Site | Bonn | Nordrhein-Westfalen | Germany | 53127 |
| 75 | GSK Investigational Site | Koeln | Nordrhein-Westfalen | Germany | 50668 |
| 76 | GSK Investigational Site | Koeln | Nordrhein-Westfalen | Germany | 50674 |
| 77 | GSK Investigational Site | Berlin | Germany | 10117 | |
| 78 | GSK Investigational Site | Berlin | Germany | 10439 | |
| 79 | GSK Investigational Site | Berlin | Germany | 10787 | |
| 80 | GSK Investigational Site | Hamburg | Germany | 20246 | |
| 81 | GSK Investigational Site | Dublin | Ireland | 8 | |
| 82 | GSK Investigational Site | Dublin | Ireland | D09 V2N0 | |
| 83 | GSK Investigational Site | Modena | Emilia-Romagna | Italy | 41124 |
| 84 | GSK Investigational Site | Roma | Lazio | Italy | 00149 |
| 85 | GSK Investigational Site | Bergamo | Lombardia | Italy | 24127 |
| 86 | GSK Investigational Site | Brescia | Lombardia | Italy | 25123 |
| 87 | GSK Investigational Site | Busto Arsizio (VA) | Lombardia | Italy | 21052 |
| 88 | GSK Investigational Site | Milano | Lombardia | Italy | 20127 |
| 89 | GSK Investigational Site | Milano | Lombardia | Italy | 20157 |
| 90 | GSK Investigational Site | Pavia | Lombardia | Italy | 27100 |
| 91 | GSK Investigational Site | Torino | Piemonte | Italy | 10149 |
| 92 | GSK Investigational Site | Aichi | Japan | 460-0001 | |
| 93 | GSK Investigational Site | Osaka | Japan | 540-0006 | |
| 94 | GSK Investigational Site | Tokyo | Japan | 108-8639 | |
| 95 | GSK Investigational Site | Tokyo | Japan | 162-8655 | |
| 96 | GSK Investigational Site | Amsterdam | Netherlands | 1091 HA | |
| 97 | GSK Investigational Site | Amsterdam | Netherlands | 1105 AZ | |
| 98 | GSK Investigational Site | Alcala de Henares | Spain | 28805 | |
| 99 | GSK Investigational Site | Burgos | Spain | 09006 | |
| 100 | GSK Investigational Site | Huelva | Spain | 21005 | |
| 101 | GSK Investigational Site | Madrid | Spain | 28006 | |
| 102 | GSK Investigational Site | Madrid | Spain | 28040 | |
| 103 | GSK Investigational Site | Majadahonda( Madrid | Spain | 28222 | |
| 104 | GSK Investigational Site | Sant Boi de Llobregat | Spain | 08830 | |
| 105 | GSK Investigational Site | Sevilla | Spain | 41014 | |
| 106 | GSK Investigational Site | Valencia | Spain | 46010 | |
| 107 | GSK Investigational Site | Valencia | Spain | 46015 | |
| 108 | GSK Investigational Site | Valencia | Spain | 46026 | |
| 109 | GSK Investigational Site | Bern | Switzerland | 3010 | |
| 110 | GSK Investigational Site | Geneve | Switzerland | CH-1205 | |
| 111 | GSK Investigational Site | Lausanne | Switzerland | 1011 | |
| 112 | GSK Investigational Site | Zuerich | Switzerland | 8091 | |
| 113 | GSK Investigational Site | Liverpool | Merseyside | United Kingdom | L7 8XP |
| 114 | GSK Investigational Site | Glasgow | United Kingdom | G12 OYN | |
| 115 | GSK Investigational Site | London | United Kingdom | SE1 9RT | |
| 116 | GSK Investigational Site | London | United Kingdom | SW10 9TH | |
| 117 | GSK Investigational Site | Manchester | United Kingdom | M8 5RB |
Sponsors and Collaborators
- ViiV Healthcare
- Janssen, LP
Investigators
- Study Director: GSK Clinical Trials, ViiV Healthcare
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 213500